Amatuximab is a chimeric monoclonal antibody designed for the treatment of cancer.[1]
Amatuximab was developed by Morphotek, Inc.
Amatuximab is also known as Anti-mesothelin monoclonal antibody MORAb-009. Amatuximab is an anti-mesothelin monoclonal antibody MORAb-009 binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing, and also called MORAb-009.
Amatuximab was developed by Morphotek, Inc.
Amatuximab is also known as Anti-mesothelin monoclonal antibody MORAb-009. Amatuximab is an anti-mesothelin monoclonal antibody MORAb-009 binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing, and also called MORAb-009.
No comments:
Post a Comment